MS risk factor | Risk* | Observations | Postulated mechanism | Alternative mechanism | |
---|---|---|---|---|---|
1. Compromise of MS-protective immune reactions favouring the biosynthesis of MLN | |||||
Human endogenous retrovirus-W (HERV-W) | X | F | HERV-W and/or syncytin-1 more frequently detectable/elevated in MS, increased levels of antibodies against HERV GAG and ENV antigens in MS, related to the activity of disease [4–8] | Overexpression of the syncytin-1 gene encoded by HERV-W disturbs redox regulation in glial cells [9] | |
Time in life of infection | E●●● | P | Virtually all MS patients experienced previous EBV-infection and had elevated levels of anti- EBV-EBNA1 antibody in comparison with control groups [3, 10, 11]. Previous EBV-infection years or decade(s) before onset of MS [12]. Expanded T-helper cell populations recognizing an epitope of the EBV antigen EBNA1 in MS patients [13] | Infection with EBV early in life can establish MS protective immunity [3, 10, 11, 14]. Infection with EBV delayed in life after immune response against an epitope nested in FENIAEGLRALLARSHVER (partial sequence of EBNA-1) is primed (see next entry) to form T- helper cells instead of regulatory T-cells essential for MS protection [14] | (Irrespective of time in life): Clonal expansion of lymphocytes in the CNS, or EBV infection triggers autoimmunity via molecular mimicry |
with Epstein-Barr virus (EBV) | § | ||||
E | F | ||||
Involvement of infection with measles, varicella and herpes simplex viruses and with 12 or more other pathogens | E●●● | P | Higher antibody-levels against diverse pathogens in particular measles, varicella, herpes simplex viruses, and EBV in MS-patients [10, 15, 16], intrathecal synthesis of antibodies against these viruses (including as in particular also rubella virus) [17, 18] | Immune responses against diverse agents generates MS-protection by cross-reaction of a self-specific CD8+-T-cell response against a peptide MPVPSAPSTMPVPSAPST belonging to the human endogenous retrovirus W (HERV-W), encoded on the complementary DNA-strand of the syncytin-1 gene [14, 19] | Immunological trigger for inflammatory demyelination |
§ | |||||
§ | |||||
Infection with Chlamydia pneumoniae and/or human herpes virus-6 | E § | F | More frequent detection of genomes of these agents in MS [15, 20, 21] More frequent IgM-specific antibodies against Chlamydia pneumoniae in paediatric onset MS [15] | Persisting infections can prime immune response against an epitope nested in FENIAEGLRALLARSHVER (partial sequence of EBV EBNA-1) to induce T-helper cells [14] | |
Worm infestation | E●● | P | Worm infestation less frequent in MS and treatment of worm infections leads to relapse of MS [22] | Contributes an immune stimulatory context that favours the generation of regulatory T-cells | |
Antihistamines | E w | P | Protective effects of antihistamines in MS [23] | Antihistamines suppress unfavourable allergic reactions competing with 'anti-parasite’-like reactions | |
HLA-polymorphism | G | P | Main HLA class I molecule A*0201 for the HLA-A0201 associated with a significantly reduced MS risk (OR = 0.52, P = 0.0015) [24] | Ability of HLA-polymorphism for immune presentation of the peptide MPVPSAPSTMPVPSAPST is good such as with HLA-A0201 (frequency of about 30% in a European population) [14] | See the text |
Interleukin-2 receptor α (IL-2Rα) | G | P | Mutations in IL-2Rα gene in MS more frequent [25] | Component of the CD-25 molecule of regulatory T-cells, critical involvement of these cells in MS-protection | |
Interleukin-7 receptor α (IL-7Rα) | G | P | Mutations in IL-7Rα gene in MS more frequent [26] | Important for maintenance of CD8+-T-cell memory, critical is a long-persisting MS-protective cellular immune reaction | |
n-3-polyunsaturated fatty acids | E | P | Reduced MS risk with diet rich in n-3 poly-unsaturated fatty acids [27] | Dietary factors leading to an enrichment of ganglioside-content of T-cells. The MS-protective immune reaction seems to be an immune repair mediated by gangliosides [14, 19, 28, 29] | |
2. Factors favouring the biosynthesis of MLN not predominantly involving the immune system | |||||
Vitamin D-deficiency | E●●● § | F | Month of birth-effect [30, 31]. Low levels of vitamin D in MS patients [32–34] | Deficiency pre-birth and after birth reduces intracellular glutathione [35] | Levels of vitamin D experienced in utero can have long-lasting effects on the development of numerous organ systems, including the CNS; during life, vitamin D has clear immunomodulatory functions |
Low sun exposure | E●● | F | Influence of place of residence, MS risk increases with higher latitude [3, 32] | Reduced exposure to sunlight rich in UV-B dependent on geographical latitude [3, 32] | |
Selenium deficiency | E w | F | MS more frequent in regions with low levels of selenium in soil [36, 37] | Selenium deficiency reduces levels of the seleno-enzyme glutathione-peroxidase [38] | |
Female sex hormones | E § | F | Dependence of MS risk on gender. MS risk in young children indepedent from gender but increased girl/boy rate in puberty [31, 32]. Reduced MS risk in pregnancy, elevated MS risk after pregnancy and after the menopause [39] | Syncytin-1 gene has a sensitivity for female sex hormones, (gene product has physiological role in placenta) [39] | Altered antigen reactivity, tolerance, epigenetic effects |
Smoking | E●● | F | Higher risk of MS in cigarette smokers [40] | Nicotine accumulates in melanin containing cells and interferes with melanin synthesis [41] | Nitric oxide-mediated demyelination, axonal loss and epigenetic effects |
Iron-load | E | F | MS association to eating of meat [27]. Iron accumulation early in MS plaques [42, 43] | ||
3. Oxidative charging of MLN | |||||
Vitamin D-deficiency | E●●● | F | See above | See above, glutathione is needed for discharging of MLN | |
§ | |||||
Low sun exposure | E●● | F | See above | See above, glutathione is needed for discharging of MLN | |
Selenium deficiency | E w | F | See above | See above, glutathione-peroxidase is needed for discharging of MLN Iron containing MLN is charged by ionizing radiation/ cosmic radiation [49]. Cosmic radiation | |
Geomagnetic disturbances/ Cosmic radiation | E●● | F | MS relates to geomagnetic 60° latitude [1] | ||
E | F | MS association to mountain regions [50] | |||
4. Physiological influence on activity of neuromelanin | |||||
Visible light | E § | P | Increased risk of MS onset (1st attack) in the lightest months of the year [31, 51] | The hormone melatonin regulates the daily activity of neuromelanins (light-triggered day-night rhythm) | |
5. Formation of short living reactive oxygen species and radicals (ROS) by mitochondria | |||||
Psycho-physical trauma | E | F | Increased MS risk in relations to psycho-physical trauma, detection of ROS-related products in MS [52] | Traumatic events lead to the generation of ROS by mitochondria | Dysregulation of the hypothalamic-pituary-adrenal axis |
Heat/fever | E | F | Heat leads to the generation of ROS by mitochondria | ||
E | F | MS protective effect of the introduction of anti-pyretics [53] and of the antibiotic penicillin [55] | Fever leads to the generation of ROS by mitochondria | ||
Chronic stress reaction | E w | F | Decreased ubiquinone, and increased endogenous digoxin and metabolites of oxidative stress in MS [56] | Over-activation of the cellular mevalonate pathway with decrease of ubiquinone, and increase of endogenous digoxin and ROS production by mitochondria [56] | As above |
6. Formation of long-living reactive oxygen species and radicals (ROS) requiring typically nitrogen oxide as a co-substrate | |||||
Infection/Inflammation | E | F | A small blood vessel is often running through the plaque, the end stage of MS pathology [57] | Adherent polymorph nuclear cells in small blood vessels form nitrogen oxide (NO) that is not readily cleared | |
Gout | E | P | MS is extremely rare in patients with gout and levels of uric acid are about 10 to 15% lower in patients with MS [58] | Radical scavenger function of uric acid for nitrogen-containing ROS [58] | |
decreased uric acid | E | F | |||
Glatiramer-acetate | E | P | An agent with therapeutic benefit in MS | Inhibition of NO synthase of mononuclear cells [59] |